All In Biotech

Investigational drug · Phase 2

AZD1163

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "AZD1163"

First trial start

2025

Dec 15, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AZD1163", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Rheumatoid Arthritis

Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "AZD1163" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Rheumatoid Arthritis

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • AfimkibartRO7790121, RVT-3101Phase 312 trials

    Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis

  • LutikizumabABT-981Phase 38 trials

    AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis

  • TLL-018Phase 38 trials

    Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria

  • IMVT-1402Phase 37 trials

    Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus

  • FilgotinibGS-6034, GLPG0634Phase 36 trials

    Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)

  • LNK01001Phase 33 trials

    Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis

  • ABBV-722Phase 32 trials

    AbbVie · Rheumatoid Arthritis, Systemic Sclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.